Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
Shaodong HongYaxiong ZhangGengsheng YuPeijian PengJiewen PengJun JiaXuan WuYan HuangYunpeng YangQing LinXuping XiMingjun XuDongping ChenXiaojun LuRen-Sheng WangXiaolong CaoXiaozhong ChenZhixiong LinJianping XiongQin LinConghua XieZhihua LiJianji PanJingao LiShixiu WuYingni LianQuanlie YangChong ZhaoWenfeng FangLi ZhangPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Among patients with previously untreated advanced nasopharyngeal carcinoma, those who receive GP have longer OS than those receive FP. Gemcitabine plus cisplatin should be considered a preferred front-line option for these patients.